Allan Will is an operating executive with extensive experience founding, funding, operating and selling medical device companies. Will currently serves as CEO of EBR Systems; and chairman of the board of Fractyl Labs and Setpoint Medical.
Previously, as chairman of Ardian, Will led negotiations of the company’s acquisition by Medtronic, one of the largest venture-funded medical device company acquisitions in history. Will was also a founding managing director in Split Rock Partners’ Silicon Valley venture capital office, focusing on the therapeutic medical device field. Will joined Split Rock’s predecessor entity SPVC in 2002 after more than 20 years in operating roles, the last 17 as CEO of various Bay Area venture-backed startups.
Most recently, Will was founder, chairman and CEO of The Foundry, where he co-founded 11 companies including Ardian, Evalve and Concentric Medical.
Prior to The Foundry, Will was CEO of AneuRx, founded by Dr. Fogarty, to develop stent grafts for aortic aneurysms. AneuRx was acquired by Medtronic in 1996. During this period Will and Dr. Fogarty co-founded Adjacent Surgical, which was sold to General Surgical Innovations in 1996. In 1994, Will led a $2 billion leveraged buyout attempt of the Eli Lilly cardiovascular device businesses, which later became Guidant Corporation. Previously, Will was president and CEO of Devices for Vascular Intervention (DVI), which was acquired by Eli Lilly and Company in 1989.
Will is also an inventor on more than 30 issued patents.
He earned his master’s degree in management from the Massachusetts Institute of Technology in 1981.
